Physician profile
Steven C Smith
NPI 1235116971
$963.54
in general payments reported to CMS, 2019-2025
14 companies · $15.76 in 2025
The $15.76 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $113 · 2021: $110 · 2022: $165 · 2024: $99.24 · 2025: $15.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $382.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $160.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.20 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $57.67 | 2022 | |
| Silk Road Medical, INC. | $48.02 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Merck Sharp & Dohme LLC | $39.42 | 2019 | |
| Amgen INC. | $35.29 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $31.48 | 2020-2022 | |
| Gilead Sciences, INC. | $28.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $17.00 | 2019 | |
| Shire North American Group INC | $16.52 | 2019 | |
| Dexcom, INC. | $15.76 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $12.88 | 2019 | |
| Emd Serono, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.